A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06804103 In Patients With Human Epidermal Growth Factor Receptor 2 (her2) Positive Solid Tumors

Trial Profile

A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06804103 In Patients With Human Epidermal Growth Factor Receptor 2 (her2) Positive Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2018

At a glance

  • Drugs PF-06804103 (Primary)
  • Indications Breast cancer; Gastric cancer; Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 19 Jul 2018 Planned End Date changed from 18 Nov 2020 to 23 Feb 2021.
    • 19 Jul 2018 Planned primary completion date changed from 18 Nov 2020 to 23 Feb 2021.
    • 01 May 2018 Planned End Date changed from 2 Dec 2020 to 18 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top